How much do paid clinical trials in Fort Wayne pay?

Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.

Do I need to be sick to join a clinical trial in Fort Wayne?

No. Many studies recruit healthy volunteers, especially early-phase studies run at dedicated research centers. Others need participants diagnosed with a specific condition. Every trial lists its eligibility criteria — age range, condition, medications — and the study team screens you before enrollment.

What is the difference between a research center and a hospital study in Fort Wayne?

Dedicated research centers (listed on this page with their Google ratings) run studies as their core business — often healthy-volunteer and vaccine studies with structured compensation. Hospital and university studies tend to focus on patients with specific conditions. Both types are registered and IRB-supervised.

How often do new paid studies open in Fort Wayne?

Constantly — trials open and close enrollment every week. This page is refreshed weekly from the NIH registry. Join the email alert to be notified when a new study opens within 30 miles of Fort Wayne.

Can I be in more than one clinical trial at a time?

Generally no — most studies exclude participants currently enrolled in another trial, and paid Phase 1 studies enforce a washout period (often 30 days or more) between studies. Frequent healthy volunteers in Fort Wayne typically complete one or two studies per year.

Paid Clinical Trials Fort Wayne, IN — 112 Studies Recruiting (Jul 2026)

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck Phase 1 Interventional 1,006 participants sought

Fort Wayne Medical Oncology and Hematology, Inc — Fort Wayne, Indiana (3.0 mi) · Sponsor: Seagen, a wholly owned subsidiary of Pfizer

See eligibility & contact on ClinicalTrials.gov (NCT04389632)

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Prostate Cancer Phase 4 Interventional 700 participants sought

Parkview Research Center — Fort Wayne, Indiana (3.0 mi) · Sponsor: Novartis Pharmaceuticals

See eligibility & contact on ClinicalTrials.gov (NCT05803941)

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Phase 3 Interventional 582 participants sought

Research Site — Fort Wayne, Indiana (3.0 mi) · Sponsor: AstraZeneca

See eligibility & contact on ClinicalTrials.gov (NCT06350097)

Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions

Pancreatic Cyst N/A Observational 500 participants sought

Parkview Hospital Randallia — Fort Wayne, Indiana (3.0 mi) · Sponsor: Ohio State University Comprehensive Cancer Center

See eligibility & contact on ClinicalTrials.gov (NCT03492151)

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Breast Cancer, Breast Cancer Metastatic Phase 1, Phase 2 Interventional 150 participants sought

Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana (3.0 mi) · Sponsor: Incyclix Bio

See eligibility & contact on ClinicalTrials.gov (NCT05735080)

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Breast Cancer, Early Breast Cancer Phase 3 Interventional 4,300 participants sought

Research Site — Fort Wayne, Indiana (3.0 mi) · Sponsor: AstraZeneca

See eligibility & contact on ClinicalTrials.gov (NCT05774951)

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 Phase 2, Phase 3 Interventional 613 participants sought

Radiation Oncology Associates PC — Fort Wayne, Indiana (3.0 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT01810913)

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Endometrial Cancer Phase 3 Interventional 1,123 participants sought

Parkview Research Center ( Site 6008) — Fort Wayne, Indiana (3.0 mi) · Sponsor: Merck Sharp & Dohme LLC

See eligibility & contact on ClinicalTrials.gov (NCT06952504)

BioPoly® Partial Resurfacing Knee Implant IDE

Knee Pain Chronic, Knee Osteoarthritis N/A Interventional 152 participants sought

Dupont Hospital — Fort Wayne, Indiana (3.0 mi) · Sponsor: BioPoly LLC

See eligibility & contact on ClinicalTrials.gov (NCT06915363)

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Non-small Cell Lung Cancer Phase 2, Phase 3 Interventional 1,260 participants sought

Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana (3.0 mi) · Sponsor: BioNTech SE

See eligibility & contact on ClinicalTrials.gov (NCT06712316)

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer Phase 3 Interventional 780 participants sought

Parkview Research Center at Parkview Regional Medical Center ( Site 0089) — Fort Wayne, Indiana (3.0 mi) · Sponsor: Merck Sharp & Dohme LLC

See eligibility & contact on ClinicalTrials.gov (NCT06312137)

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Focal Seizure, Epilepsy Phase 3 Interventional 333 participants sought

Indiana University Health Fort Wayne Neurology — Fort Wayne, Indiana (3.0 mi) · Sponsor: Rapport Therapeutics Inc.

See eligibility & contact on ClinicalTrials.gov (NCT07563881)

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Acute Coronary Syndrome Phase 3 Interventional 2,000 participants sought

Research Site — Fort Wayne, Indiana (3.0 mi) · Sponsor: DalCor Pharmaceuticals

See eligibility & contact on ClinicalTrials.gov (NCT05918861)

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Heart Failure Phase 2 Interventional 620 participants sought

NexGen Research — Fort Wayne, Indiana (3.0 mi) · Sponsor: Pfizer

See eligibility & contact on ClinicalTrials.gov (NCT06991257)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma Phase 3 Interventional 1,210 participants sought

Parkview Regional Medical Center — Fort Wayne, Indiana (3.0 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT04267848)

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Breast Cancer N/A Observational 30,000 participants sought

Parkview Health — Fort Wayne, Indiana (3.0 mi) · Sponsor: Agendia

See eligibility & contact on ClinicalTrials.gov (NCT03053193)

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Previously Treated Non-Small Cell Lung Cancer Phase 2, Phase 3 Interventional 10,000 participants sought

Parkview Regional Medical Center — Fort Wayne, Indiana (3.0 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT03851445)

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer Phase 2 Interventional 180 participants sought

Fort Wayne Medical Oncology And Hematology /ID# 277336 — Fort Wayne, Indiana (3.0 mi) · Sponsor: AbbVie

See eligibility & contact on ClinicalTrials.gov (NCT07155174)

The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families

Mental Health, Conflict N/A Interventional 1,800 participants sought

Fort Wayne Center for Children and Families — Fort Wayne, Indiana (3.0 mi) · Sponsor: University of Notre Dame

See eligibility & contact on ClinicalTrials.gov (NCT04980794)

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

Aortic Stenosis, Coronary Artery Disease N/A Interventional 4,000 participants sought

Parkview Research Center — Fort Wayne, Indiana (3.0 mi) · Sponsor: University of British Columbia

See eligibility & contact on ClinicalTrials.gov (NCT04634240)

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

Aortic Stenosis N/A Observational 225 participants sought

Parkview Health — Fort Wayne, Indiana (3.0 mi) · Sponsor: Medtronic Cardiovascular

See eligibility & contact on ClinicalTrials.gov (NCT06777368)

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Peripheral Vascular Diseases N/A Observational 5,000 participants sought

St. Joseph Hospital/Dupont Hospital — Fort Wayne, Indiana (3.0 mi) · Sponsor: Boston Scientific Corporation

See eligibility & contact on ClinicalTrials.gov (NCT04674969)

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

HR+/HER2- Breast Cancer Phase 3 Interventional 1,056 participants sought

Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana (3.0 mi) · Sponsor: BeOne Medicines

See eligibility & contact on ClinicalTrials.gov (NCT07492641)

BostonGene and Exigent Genomic INsight Study

Breast Cancer, Non-small Cell Lung Cancer N/A Observational 400 participants sought

Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana (3.0 mi) · Sponsor: BostonGene

See eligibility & contact on ClinicalTrials.gov (NCT06272864)

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma Phase 2 Interventional 40 participants sought

Ohio State University-Telemedicine — Fort Wayne, Indiana (3.0 mi) · Sponsor: Sameek Roychowdhury

See eligibility & contact on ClinicalTrials.gov (NCT06906562)

Paid Clinical Trials in Fort Wayne, IN

Studies recruiting near Fort Wayne right now